18 March 2021
We recently shared details of the long-term future of our patient studies on children and young people with juvenile idiopathic arthritis (JIA): a merger of British Society for Rheumatology (BSR)'s Etanercept study and Versus Arthritis’ Biologics for Children with Rheumatic Diseases study, for at least four more years.
A new umbrella identity was created to celebrate this partnership and unify our studies (see below) – welcome to the UK JIA Biologics Register.
Our new identity brings to life the important work behind the study and showcases our combined ambitions to develop a deeper understanding of JIA that will lead to improved patient care. With patients in mind, it's important for us to keep sight of the children and young people that we care for.
Our new brand takes inspiration from joints in the body and building block toys to create a visual language and couples that with a warm colour palette: children and young people are the inspiration and heart of the brand. You can see examples of this below.
Dr Jacqui Clinch, BSR Vice President and a consultant paediatric and adolescent rheumatologist, says: "I'm delighted that BSR and Versus Arthritis have signed an agreement to collaborate on the UK JIA Biologics Register to facilitate the continuation of studies evaluating the impact of biologics in paediatric and adolescent rheumatological conditions – a real gamechanger.
"This is a great example of how, by working inclusively with national and international partners, our BSR paediatric and adolescent community can make such a difference. I'm committed, as your Vice President, to supporting as many pieces of joint working that I can during my tenure."
The UK JIA Biologics Register is delivered on behalf of BSR/VA by the University of Manchester.